# Phase 7 — Business Output Quality Review

**Date:** 2026-06-08
**Project:** VasoSeal Pro X (Class IIb)
**Reviewer:** Independent quality auditor (read-only)

---

## 1. Output Completeness

| Artifact | Expected | Actual | Status |
|:---|:---:|:---:|:---:|
| CER_REASONING_LEDGER | Present, non-empty | 4 claims | ✅ |
| IFU_CLAIM_EVOLUTION_LEDGER | 5-stage per claim | 4 claims × 5 stages | ✅ |
| BENCHMARK_DERIVATION_TRACE | Per-endpoint rationale | 2 endpoints | ✅ |
| G46 Report | 13 conditions | 13 conditions | ✅ |
| CER_INPUT_PACKAGE | All required keys | 7 top-level keys | ✅ |

---

## 2. Claim Quality Assessment

### C-01: "Achieves hemostasis within 3 minutes in >=90% of patients"
- Classification: `clinical_performance` ✅
- Support: `direct` with 3 sources (RCT, Prospective, Meta-analysis) ✅
- Strength: `strong` — correct: direct + >=2 sources ✅
- Gap: `no_gap` — correct: evidence present ✅

### C-02: "Device-related major adverse event rate <2%"
- Classification: `clinical_safety` ✅
- Support: `direct` with 1 source (Registry, N=2000) ✅
- Strength: `moderate` — correct: direct + 1 source ✅
- Gap: `no_gap` — acceptable: single registry study with large N ✅

### C-03: "Ergonomic handle design reduces operator fatigue"
- Classification: `usability` ✅
- Support: `insufficient` — no evidence linked ✅
- Strength: `limited` — correct: insufficient evidence ✅
- Gap: `PMCF` — correct: evidence gap triggers PMCF ✅

### C-04: "The revolutionary VasoSeal Pro X guarantees perfect closure..."
- Classification: `clinical_performance` ✅
- Support: `direct` with 2 sources ✅
- Marketing detected: ✅ `marketing_language_detected=true`
- Gap: `claim_narrowing` — correct: wording issue, not evidence issue ✅
- **G46 BLOCKED on this claim** — correct behavior ✅

---

## 3. Pattern Analysis

### Strengths
1. **Clear evidence-to-claim mapping.** Each claim has explicit evidence support type.
2. **Graded conclusions.** Conclusion strength follows evidence quality: direct+3→strong, direct+1→moderate, insufficient→limited.
3. **Gap disposition specificity.** PMCF for evidence gap, claim_narrowing for wording issue — not generic.
4. **Marketing detection functional.** C-04 correctly identified despite having evidence links.

### Areas for Improvement (Future)
1. C-02 (safety claim) would benefit from explicit RMF/GSPR linkage in the reasoning ledger.
2. C-03 (usability) PMCF recommendation could be more specific about study design.
3. Generic fallback benchmark for "vascular_closure" domain could be enriched with domain-specific template.

---

## 4. Regulatory Soundness

| Principle | Status | Evidence |
|:---|:---:|:---|
| No unsupported claims in conclusions | ✅ | C-03 limited + PMCF; C-04 blocked |
| Evidence traceability | ✅ | All claims linked to specific PMIDs |
| IFU not treated as gold standard | ✅ | Marketing language flagged |
| PMCF not universal patch | ✅ | claim_narrowing for wording issue |
| Conclusion strength evidence-based | ✅ | Derived from support type + count |

---

## 5. Quality Verdict

**Business output quality: ACCEPTABLE.** The generated artifacts demonstrate expert-reasoning behavior. Claims are properly classified, evidence is graded, conclusions are capped by evidence strength, and gaps are specifically dispositioned. Marketing language is detected and quarantined. The system behaves like a regulatory engineer would expect.
